Prevention of antibody-mediated elimination of ligand-targeted liposomes by using poly(ethylene glycol)-modified lipids.

One of the major obstacles in the development of ligand-targeted liposomes is poor liposome circulation longevity as a result of antibody-mediated elimination of these highly immunogenic carriers. Because studies from our laboratory suggest that it is not possible to reduce the immunogenicity of ligand-conjugated liposomes by using surface-grafted poly(ethylene glycol) (PEG), we investigated the usefulness of PEG in protecting hapten-conjugated liposomes from elimination by an existing immune response that was previously established against the hapten. Using biotin as a model hapten, a strong biotin-specific antibody response was generated in mice by using bovine serum albumin-biotin. When these animals were challenged with liposomes containing biotin-conjugated lipid (1 or 0.1%), these liposomes were rapidly eliminated. Incorporation of PEG-lipids into these liposomes substantially reduced biotin-specific antibody binding as measured using an in vitro antibody consumption assay. However, depending on the hapten concentration, significant reductions in antibody binding through the use of PEG-lipids may not be sufficient to protect these liposomes from rapid elimination in vivo. Complete protection of liposomes was only achieved when the biotin concentration on liposome surface was low (0.1%) and with 5 mol% of either 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-n-[methoxy(polyethylene glycol)-2000] or 1,2-dipalmatoyl-sn-glycero-3-phosphoethanolamine-n-methoxy(polyethylene glycol)-2000]. The use of 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-n-[methoxy(polyethylene glycol)-2000] (up to 15 mol%) was not effective in protecting liposomes from rapid elimination in vivo, indicating the limited usefulness of this highly exchangeable PEG-lipid. In conclusion, our in vivo and in vitro data indicate that liposomes can be protected from antibody-mediated elimination by using the right type and concentration of PEG-lipids. This result has important implication in the development of ligand-targeted liposomes.

[1]  M. Bally,et al.  Enhanced immune response to T-independent antigen by using CpG oligodeoxynucleotides encapsulated in liposomes. , 2001, Vaccine.

[2]  M. Bally,et al.  Intermembrane transfer of polyethylene glycol-modified phosphatidylethanolamine as a means to reveal surface-associated binding ligands on liposomes. , 2001, Biochimica et biophysica acta.

[3]  M. Bally,et al.  Surface-associated serum proteins inhibit the uptake of phosphatidylserine and poly(ethylene glycol) liposomes by mouse macrophages. , 2001, Biochimica et biophysica acta.

[4]  M. Bally,et al.  Selective protein interactions with phosphatidylserine containing liposomes alter the steric stabilization properties of poly(ethylene glycol). , 2001, Biochimica et biophysica acta.

[5]  W. Oyen,et al.  Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. , 2000, The Journal of pharmacology and experimental therapeutics.

[6]  D. Tzemach,et al.  Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: in vitro studies. , 1999, Bioconjugate chemistry.

[7]  D. Devine,et al.  Inhibition of liposome-induced complement activation by incorporated poly(ethylene glycol)-lipids. , 1998, Archives of biochemistry and biophysics.

[8]  C. Miller,et al.  Liposome-cell interactions in vitro: effect of liposome surface charge on the binding and endocytosis of conventional and sterically stabilized liposomes. , 1998, Biochemistry.

[9]  S. Lesieur,et al.  New sterically stabilized vesicles based on nonionic surfactant, cholesterol, and poly(ethylene glycol)-cholesterol conjugates. , 1998, Biophysical journal.

[10]  M. Bally,et al.  An immune response to ovalbumin covalently coupled to liposomes is prevented when the liposomes used contain doxorubicin. , 1997, Journal of immunological methods.

[11]  M S Newman,et al.  Immunogenicity and pharmacokinetic attributes of poly(ethylene glycol)-grafted immunoliposomes. , 1997, Biochimica et biophysica acta.

[12]  S W Hui,et al.  Grafted poly-(ethylene glycol) on lipid surfaces inhibits protein adsorption and cell adhesion. , 1997, Biochimica et biophysica acta.

[13]  M. Bally,et al.  Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol). , 1997, The Journal of pharmacology and experimental therapeutics.

[14]  John W. Park,et al.  Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. , 1997, Biochemistry.

[15]  S. Hirota,et al.  Effect of sterical stabilization on macrophage uptake in vitro and on thickness of the fixed aqueous layer of liposomes made from alkylphosphocholines. , 1996, Biochimica et biophysica acta.

[16]  P. Cullis,et al.  Poly(ethylene glycol)--lipid conjugates regulate the calcium-induced fusion of liposomes composed of phosphatidylethanolamine and phosphatidylserine. , 1996, Biochemistry.

[17]  D. Needham,et al.  Range and magnitude of the steric pressure between bilayers containing phospholipids with covalently attached poly(ethylene glycol). , 1995, Biophysical journal.

[18]  L. Huang,et al.  Targetability of novel immunoliposomes modified with amphipathic poly(ethylene glycol)s conjugated at their distal terminals to monoclonal antibodies. , 1995, Biochimica et biophysica acta.

[19]  N. Phillips,et al.  Immunogenicity of immunoliposomes: reactivity against species-specific IgG and liposomal phospholipids. , 1995, Immunology letters.

[20]  John W. Park,et al.  Development of anti-p185HER2 immunoliposomes for cancer therapy. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[21]  G. Storm,et al.  Immunoliposomes in vivo. , 1994, ImmunoMethods.

[22]  N. Phillips,et al.  Immunoliposome targeting to murine CD4+ leucocytes is dependent on immune status. , 1994, Journal of immunology.

[23]  M. Woodle,et al.  Sterically stabilized liposomes. , 1992, Biochimica et biophysica acta.

[24]  A. Emili,et al.  Immunogenicity of immunoliposomes. , 1991, Immunology letters.

[25]  T M Allen,et al.  Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. , 1991, Biochimica et biophysica acta.

[26]  C. Leclerc,et al.  Carrier-induced epitopic suppression is initiated through clonal dominance. , 1989, Journal of immunology.

[27]  M. N. Jones,et al.  The characterisation of liposomes with covalently attached proteins. , 1989, Biochimica et biophysica acta.

[28]  L. Mayer,et al.  Vesicles of variable sizes produced by a rapid extrusion procedure. , 1986, Biochimica et biophysica acta.

[29]  J. Owicki,et al.  Interaction of antibodies with liposomes bearing fluorescent haptens. , 1984, Biochimica et biophysica acta.

[30]  P. Shek,et al.  Immune response mediated by liposome-associated protein antigens. III. Immunogenicity of bovine serum albumin covalently coupled to vesicle surface. , 1983, Immunology.

[31]  R. Juliano,et al.  Interactions of liposomes with the reticuloendothelial system. II: Nonspecific and receptor-mediated uptake of liposomes by mouse peritoneal macrophages. , 1982, Biochimica et biophysica acta.

[32]  M. Bally,et al.  A two-step targeting approach for delivery of doxorubicin-loaded liposomes to tumour cells in vivo , 2004, Cancer Chemotherapy and Pharmacology.

[33]  J. Cohen,et al.  Sterically stabilized liposomes: physical and biological properties. , 1994, Journal of drug targeting.

[34]  M. Lascombe,et al.  Three-dimensional structure of antibodies. , 1988, Annual review of immunology.

[35]  B. Geiger,et al.  Dynamics of antibody‐ and lectin‐mediated endocytosis of hapten‐containing liposomes by murine macrophages , 1981, European journal of immunology.

[36]  R. Poljak,et al.  Three-dimensional structure of immunoglobulins. , 1979, Annual review of biochemistry.